1FRANKLIN S S,KHAN S A,WONG N D,et al.Is pulse pressure useful in predict-ing risk for coronary heart disease?[J].Circulation,1999,100:354-360.
2BENETOS A,RUDNICHI A,SAFAR M,et al.Pulse pressure and cardiovasculal mortality in normotensive and hypertensive subjects[J].Hypertension,1998,32:560-564.
3VERDECCHIA P,SCHILLACI G,REBOLDI G,et al.Diffferent prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension[J].Circulation,2001,103:2579-2584.
4CERAVOLO R,MAIO R,PUJIA A,et al.Pulse pressure and endothelial dysfunction in never-treated hypertensive patients[J].J Am Coll Cardiol,2003,41:1753-1758.
5FRANKLIN S S,GUSTIN W,WONG N D,et al.Hemodynamic pattens of age-related change in blood pressure:The Framingham Study[J].Circulation,1997,96:308-315.
6Fathi R,Marwick TH.Noninvasive tests of vascular function and structure: why and how to perform them[].American Heart Journal.2001
7Crouse JR,Harpold GH,Kahl FR,et al.Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound[].Stroke.1986
8Celermajer DS,Sorensen KE,Gooch VM,et al.Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[].The Lancet.1992
9Zanchetti A.Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials[].Clinical and Experimental Hypertension.1996
10Prisant LM,Zemel PC,Nichols FT,et al.Carotid plaque associations among hypertensive patients[].Archives of Internal Medicine.1993
2Runikhian NK, Tkacheva ON. Efficacy of long acting calcium antagonist felodipine in smoking women with essential arterial hypertension[J]. Kardiologiia, 2008,48 ( 9 ) : 50-52.
3Weir MR,Crkielair N,Levy D,et al. Evaluation of the dose response with valsartan and val sartan/hydrochlorothiazide in patients with essential hypertension[J]. J Clin Hypertens,2007,9(2):103-112.
4Barehmann J,Ansari A,Mahla G,et al.Effective and safe reduction of blood pressure with tile combination of amlodipine 5mg and valsartan 160mg in hypertensive patients not controlled by calcium channel blocker monotherapy[J]. Adv Ther, 2008,25 (5) : 399-411.
5张继平.临床内科学[M].天津:天津科学技术出版社,1998.
6Derendorf H, Lesko L J, Chaikin P, et al. Pharmaeokinetic/pharmacodynamic modeling in drug research and development[J]. J Clin Pharmacol, 2000,40 (2) : 1 399.
7Van steeg TJ, Freijer J, Danhof M, et al. Pharmaeokinetic-pharmacodynamic modeling of S (-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint[J]. Br J Pharmacol, 2007,151 (3) :356.
